About Transmembrane 6 superfamily member 2
Transmembrane 6 superfamily member 2 (TM6SF2) is a protein
from Homo sapiens identified by UniProt accession
Q9BZW4, 377 residues long.
MolForge cross-references it against 0 known binders and
239 disease associations.
Target properties
| Protein name | Transmembrane 6 superfamily member 2 |
| UniProt accession | Q9BZW4 |
| Gene | TM6SF2 |
| Organism | Homo sapiens |
| Length | 377 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (239)
Diseases linked to this target (Open Targets).
- triglyceride measurement · score 0.45
- total cholesterol measurement · score 0.43
- low density lipoprotein cholesterol measurement · score 0.42
- serum alanine aminotransferase measurement · score 0.42
- alkaline phosphatase measurement · score 0.40
- vitamin D measurement · score 0.39
- bilirubin measurement · score 0.38
- aspartate aminotransferase measurement · score 0.37
- type 2 diabetes mellitus · score 0.37
- Hypercholesterolemia · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BZW4-F1 | alphafold | PREDICTED | 90.99 | — |
Amino-acid sequence (377 residues)
MDIPPLAGKI AALSLSALPV SYALNHVSAL SHPLWVALMS ALILGLLFVA VYSLSHGEVS YDPLYAVFAV FAFTSVVDLI IALQEDSYVV GFMEFYTKEG EPYLRTAHGV FICYWDGTVH YLLYLAMAGA ICRRKRYRNF GLYWLGSFAM SILVFLTGNI LGKYSSEIRP AFFLTIPYLL VPCWAGMKVF SQPRALTRCT ANMVQEEQRK GLLQRPADLA LVIYLILAGF FTLFRGLVVL DCPTDACFVY IYQYEPYLRD PVAYPKVQML MYMFYVLPFC GLAAYALTFP GCSWLPDWAL VFAGGIGQAQ FSHMGASMHL RTPFTYRVPE DTWGCFFVCN LLYALGPHLL AYRCLQWPAF FHQPPPSDPL ALHKKQH
Explore Transmembrane 6 superfamily member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets